Clinical Trial Update: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/Phase 2 trial of TQB3909 tablets for relapsed or refractory mantle cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• TQB3909

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED